NasdaqGS:STOKBiotechs
Assessing Stoke Therapeutics (STOK) Valuation After Recent Share Price Cooling
Recent share performance and business context
Stoke Therapeutics (STOK) has given investors a mixed ride recently, with the stock down about 10% over the past month and 15% over the past 3 months, despite a much stronger total return over the past year.
At a recent close of US$30.01 and a market value of about US$1.88b, the company sits squarely in mid cap territory, backed by a focused pipeline built around its TANGO platform for treating severe genetic diseases.
See our latest analysis for...